59.35
price down icon0.70%   -0.42
after-market Handel nachbörslich: 59.35
loading
Schlusskurs vom Vortag:
$59.77
Offen:
$57.5
24-Stunden-Volumen:
2.04M
Relative Volume:
1.49
Marktkapitalisierung:
$7.33B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
19.65
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
-6.99%
1M Leistung:
-2.67%
6M Leistung:
+10.21%
1J Leistung:
+44.51%
1-Tages-Spanne:
Value
$56.38
$61.81
1-Wochen-Bereich:
Value
$56.38
$64.17
52-Wochen-Spanne:
Value
$37.73
$66.00

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Firmenname
Halozyme Therapeutics Inc
Name
Telefon
(858) 794-8889
Name
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Mitarbeiter
350
Name
Twitter
@halozymeinc
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
HALO's Discussions on Twitter

Vergleichen Sie HALO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
HALO
Halozyme Therapeutics Inc
59.35 7.33B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-07 Herabstufung Wells Fargo Overweight → Equal Weight
2024-09-19 Herabstufung JP Morgan Overweight → Neutral
2024-06-07 Herabstufung Piper Sandler Overweight → Neutral
2024-02-29 Eingeleitet TD Cowen Outperform
2023-07-24 Herabstufung Goldman Buy → Neutral
2023-07-24 Eingeleitet H.C. Wainwright Buy
2023-05-10 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Berenberg Buy
2023-03-16 Herabstufung SVB Securities Outperform → Market Perform
2022-12-21 Fortgesetzt Morgan Stanley Overweight
2022-11-28 Eingeleitet Wells Fargo Overweight
2022-09-09 Eingeleitet Morgan Stanley Overweight
2022-05-23 Eingeleitet SVB Leerink Outperform
2021-06-14 Eingeleitet Evercore ISI Outperform
2021-05-17 Eingeleitet SVB Leerink Outperform
2021-05-11 Herabstufung Piper Sandler Overweight → Neutral
2021-01-21 Bestätigt The Benchmark Company Buy
2020-12-17 Eingeleitet Berenberg Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-07-01 Eingeleitet The Benchmark Company Buy
2020-02-05 Hochstufung Piper Sandler Neutral → Overweight
2020-01-09 Hochstufung BMO Capital Markets Market Perform → Outperform
2020-01-08 Eingeleitet Goldman Buy
2019-11-05 Hochstufung Barclays Underweight → Equal Weight
2018-10-19 Fortgesetzt Piper Jaffray Neutral
2018-05-11 Herabstufung Barclays Equal Weight → Underweight
2018-01-24 Eingeleitet Goldman Neutral
2017-10-16 Bestätigt Piper Jaffray Overweight
2017-01-06 Herabstufung Citigroup Buy → Neutral
2016-11-03 Eingeleitet Deutsche Bank Buy
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-11-18 Eingeleitet Citigroup Buy
2015-09-22 Eingeleitet Barclays Overweight
2015-06-22 Bestätigt JP Morgan Overweight
2015-03-03 Bestätigt UBS Buy
2015-02-18 Bestätigt MLV & Co Buy
2015-01-08 Bestätigt MLV & Co Buy
Alle ansehen

Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten

pulisher
02:52 AM

J&J, Halozyme win EU nod for injectable Rybrevant (JNJ:NYSE) - Seeking Alpha

02:52 AM
pulisher
12:49 PM

EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com Canada

12:49 PM
pulisher
10:55 AM

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve

10:55 AM
pulisher
09:55 AM

Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq

09:55 AM
pulisher
09:36 AM

EC approves new lung cancer treatment using Halozyme technology - Investing.com

09:36 AM
pulisher
09:35 AM

European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener

09:35 AM
pulisher
09:29 AM

Major EU Victory: Halozyme's ENHANZE Tech Gets Green Light for Advanced Lung Cancer - Stock Titan

09:29 AM
pulisher
Apr 03, 2025

KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Apr 03, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - The Malaysian Reserve

Mar 31, 2025
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters

Mar 27, 2025
pulisher
Mar 27, 2025

Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat

Mar 27, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Halozyme stock soars to all-time high of $65.54 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance

Mar 24, 2025
pulisher
Mar 21, 2025

Halozyme Announces Retirement of Chief Technical Officer - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Halozyme Joins the $1 Billion Club - Yahoo Finance

Mar 21, 2025
pulisher
Mar 17, 2025

AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma

Mar 17, 2025
pulisher
Mar 14, 2025

Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Zacks Research Issues Negative Outlook for HALO Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

HALO vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com

Mar 10, 2025
pulisher
Mar 10, 2025

New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN

Mar 10, 2025
pulisher
Mar 08, 2025

Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight - Fierce Pharma

Mar 06, 2025
pulisher
Mar 05, 2025

Exclusive | New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle - The Wall Street Journal

Mar 05, 2025
pulisher
Mar 05, 2025

Patent clash looms over Merck & Co.'s subcutaneous Keytruda - FirstWord Pharma

Mar 05, 2025
pulisher
Mar 05, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

Mar 05, 2025

Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
Kapitalisierung:     |  Volumen (24h):